Dentbumbo the ASX announcement is very clear as it says “and to date 15 infusions kits have been purchased” The date of the ASX release is Australia April 30. This is one of the few things in today’s announcement that is clear as otherwise it is obfuscation at its very best.
The FDA approved Ryoncil on December 19th 2024 and we are now 128 days since approval. In that time shareholders have not received clear, concise and constructive updates from the company on its Ryoncil sales rollout plan.
Currently the valuation applied to Ryoncil is the key driver of Mesoblasts share price. Yes blue sky announcements such as partnerships or FDA updates in the future will give the share price a boost but right now Ryoncil is the key driver. And what we are getting through open briefings and ASX announcements leads one to believe that the company is behind plan. Don’t forget a key reason why shorts have increased in Mesoblast to 4.5% is this very issue!
Let’s hope a more fulsome update is forthcoming which will encourage the market to fairly value Mesoblast.
MSB Price at posting:
$1.80 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)